AGO2 anticorps (AA 517-818) (FITC)

N° du produit ABIN7165093

Cet anticorps anti-AGO2 est un anticorps Lapin Polyclonal détectant AGO2 dans . Adapté pour Humain.

Aperçu rapide pour AGO2 anticorps (AA 517-818) (FITC) (ABIN7165093)

Antigène: AGO2 (Argonaute 2 (AGO2))

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp AGO2 est conjugé à/à la FITC

Application: Veuillez nous consulter SVP

Détail du produit anti-AGO2 anticorps (FITC)

Épitope: AA 517-818

Réactivité croisée: Humain

Purification: >95%, Protein G purified

Immunogène: Recombinant Human Protein argonaute-2 protein (517-818AA)

Isotype: IgG

Information d'application

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, PH 7.4

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C,-80 °C

Stockage commentaire: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Détails sur AGO2

Antigène: AGO2 (Argonaute 2 (AGO2))

Autre désignation: AGO2

Sujet:

Background: Required for RNA-mediated gene silencing (RNAi) by the RNA-induced silencing complex (RISC). The minimal RISC appears to include AGO2 bound to a short guide RNA such as a microRNA (miRNA) or short interfering RNA (siRNA). These guide RNAs direct RISC to complementary mRNAs that are targets for RISC-mediated gene silencing. The precise mechanism of gene silencing depends on the degree of complementarity between the miRNA or siRNA and its target. Binding of RISC to a perfectly complementary mRNA generally results in silencing due to endonucleolytic cleavage of the mRNA specifically by AGO2. Binding of RISC to a partially complementary mRNA results in silencing through inhibition of translation, and this is independent of endonuclease activity. May inhibit translation initiation by binding to the 7-methylguanosine cap, thereby preventing the recruitment of the translation initiation factor eIF4-E. May also inhibit translation initiation via interaction with EIF6, which itself binds to the 60S ribosomal subunit and prevents its association with the 40S ribosomal subunit. The inhibition of translational initiation leads to the accumulation of the affected mRNA in cytoplasmic processing bodies (P-bodies), where mRNA degradation may subsequently occur. In some cases RISC-mediated translational repression is also observed for miRNAs that perfectly match the 3' untranslated region (3-UTR). Can also up-regulate the translation of specific mRNAs under certain growth conditions. Binds to the AU element of the 3-UTR of the TNF (TNF-alpha) mRNA and up-regulates translation under conditions of serum starvation. Also required for transcriptional gene silencing (TGS), in which short RNAs known as antigene RNAs or agRNAs direct the transcriptional repression of complementary promoter regions.

Aliases: Ago 2 antibody, AGO2_HUMAN antibody, Argonaute 2 antibody, argonaute 2, RISC catalytic component antibody, Argonaute RISC catalytic component 2 antibody, Argonaute2 antibody, CTA-204B4.6 antibody, dAgo2 antibody, eIF 2C 2 antibody, eIF-2C 2 antibody, eIF2C 2 antibody, Eif2c2 antibody, Eukaryotic translation initiation factor 2C 2 antibody, Eukaryotic translation initiation factor 2C subunit 2 antibody, hAgo2 antibody, MGC3183 antibody, PAZ Piwi domain protein antibody, PPD antibody, Protein argonaute-2 antibody, Protein slicer antibody, Q10 antibody, Slicer protein antibody

UniProt: Q9UKV8

Pathways: Fc-epsilon Receptor Signaling Pathway, Regulatory RNA Pathways, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Ribonucleoprotein Complex Subunit Organization